Relmada" Positive Efficacy and Safety Results in Phase 3 Long-Term Study in Major Depressive Disorder

 

• Patients newly treated with REL-1017 for up to one year experienced rapid, clinically meaningful, and sustained improvements in depressive symptoms and associated functional impairment
• Long-term dosing with REL-1017 was well-tolerated, with low rates of adverse events and discontinuations due to adverse events, and no new safety signals were detected

https://www.biospace.com/article/releases/relmada-therapeutics-announces-efficacy-and-safety-results-from-the-phase-3-long-term-study-of-rel-1017-in-major-depressive-disorder/